General Information
Tafamidis free acid form is a non-nonsteroidal anti-inflammatory benzoxazole derivative. Tafamidis, sold under the brand name Vyndamax among others, was developed by FoldRX, now acquired by Pfizer. It was approved by FDA in 2019.
About the API
Systematic name
2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic acid
Trade name(s)
Vyndamax
Molecular Formula
C14H7Cl2NO3
Molecular Weight
308.114
Therapeutic category
Cardiovascular
Available formulations
Oral Solid
Regulations
US DMF
US DMF